AbbVie shares results from phase 3 trial for atogepant migraine treatment
AbbVie has shared positive results from its phase 3 ELEVATE study, which assessed atogepant for the preventative treatment of episodic migraines in patients who have previously had two to four unsuccessful classes of oral preventive medications.
The study results demonstrated that adult patients treated with the atogepant 60mg dose once daily experienced a decrease of 4.2 days in their mean monthly migraine days (MMDs) across the 12-week treatment period compared to the placebo group.
All primary and secondary endpoints were met and the drug demonstrated a statistically significant reduction in MMDs compared to the placebo group. The full data was expected to be presented during the Emerging Science session on 25 April 2023 at the 2023 American Academy of Neurology (AAN) Annual Meeting in Boston, US.
Dawn Carlson, vice president of neuroscience development at AbbVie, commented: "We understand that people living with migraine endure a chronic neurological disease and we are dedicated to providing them the best chance to live a life with less frequent migraines. The data presented at AAN underscores the important role of atogepant, not only as a treatment option for people living with episodic migraine but also for those whose previous treatments failed to help reduce the impact of migraine on their lives."
Professor Patricia Pozo-Rosich MD PhD, head of Neurology Section, Vall d’Hebron Hospital and Institute of Research, Spain, added: "For those living with migraine, the path towards effective treatment can be a long and complex journey. The ELEVATE trial demonstrates atogepant as a once-daily oral treatment that can significantly reduce monthly migraine days across a lifelong disorder, allowing people to experience relief in their daily lives, including those who have previously been failed by other preventive migraine treatments."
Pharmaceutical Industry news, analysis and insights